What Separates Promising Alzheimer’s Research From Proven Therapy?

The gap between promising Alzheimer's research and proven therapy is measured in years of clinical evidence, billions of dollars, and the regulatory...

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Promising research sits at the center of this question for families navigating dementia.

The gap between promising Alzheimer’s research and proven therapy is measured in years of clinical evidence, billions of dollars, and the regulatory journey from laboratory discovery to patient treatment. A drug showing impressive results at shrinking amyloid plaques in the brain—the hallmark of Alzheimer’s disease—may never translate into meaningful cognitive benefit for patients. This is why lecanemab (Leqembi), approved by the FDA in January 2023, represents a watershed moment: it moved beyond merely reducing amyloid to demonstrably slowing cognitive decline by 27% over 18 months, becoming one of the first disease-modifying therapies to clear the highest bar for proof.

The difference between these two categories is not just scientific; it’s regulatory, statistical, and deeply practical. A drug can show all the right biomarker changes—lower amyloid levels, reduced tau tangles, improved brain imaging—and still fail if it doesn’t slow the actual cognitive decline that patients experience. Conversely, a therapy that slows decline in a carefully controlled trial of 1,500 patients might not work the same way in a broader population or in real-world clinical settings. Understanding what separates the two requires looking at how the FDA evaluates evidence, what clinical trials must prove, and why the barriers are so deliberately high.

Table of Contents

FDA Approval Pathways Behind Promising Alzheimer’s Drugs

The FDA does not approve Alzheimer’s drugs the same way it approves medications for high cholesterol or depression. For serious conditions with few existing treatments, the FDA offers an Accelerated Approval pathway that allows a drug to reach patients faster—but with conditions. Lecanemab initially received accelerated approval based on a surrogate endpoint: the reduction of amyloid in the brain, measured through PET imaging and cerebrospinal fluid biomarkers. This was not evidence that the drug actually improved cognition; it was evidence that it did what it was designed to do chemically. The critical difference emerged when the required postmarketing confirmatory trial—the Phase III CLARITY AD study—showed that lecanemab actually slowed cognitive decline by 27% over 18 months. This pathway reveals a crucial separation between promising and proven: accelerated approval is contingent. The FDA requires manufacturers to complete and submit results from a Phase III trial that measures actual clinical benefit.

If that trial had shown no meaningful slowing of cognition despite successful amyloid reduction, the FDA could have declined to convert the accelerated approval to traditional approval. In July 2023, the FDA did convert lecanemab to traditional approval based on CLARITY AD data—but only after the evidence demonstrated genuine clinical benefit. Promising research gets you to accelerated approval; proven benefit gets you to standard FDA approval and real reimbursement from insurers. The regulatory timeline itself is part of what separates research from therapy. After a Phase III trial concludes, the FDA takes an average of 18 months to review the data, request additional information, and make a final decision. This is not bureaucratic delay; it is the time required for multiple reviewers to examine safety data from over a thousand patients, verify statistical analyses, assess the strength of evidence, and determine whether the drug’s benefits outweigh its risks. During these 18 months, a therapy that looks promising in press releases and preliminary data remains unproven in the eyes of regulators and insurance companies.

FDA APPROVAL PATHWAYS AND THE ACCELERATED APPROVAL REQUIREMENT

CLINICAL TRIAL STANDARDS AND THE EVIDENCE THRESHOLD

The FDA’s gold standard for proving Alzheimer’s therapy is the randomized, double-blind, placebo-controlled trial—a study design that eliminates bias and ensures the measured benefit is genuinely caused by the drug, not by patients’ expectations, clinician enthusiasm, or natural variation in disease progression. Recent major trials like CLARITY AD enrolled 1,500 or more participants with mild cognitive impairment or mild dementia due to Alzheimer’s. These patients are carefully screened to ensure they have amyloid pathology confirmed by biomarkers, they are at the right disease stage, and they have no complicating medical conditions that might confound the results. The cognitive decline scale used in these trials—the ADAS-Cog (Alzheimer’s Disease Assessment Scale–Cognitive subscale)—ranges from 0 to 85, with higher scores indicating worse cognition. Untreated Alzheimer’s disease typically worsens by approximately 8 points per year on this scale. When lecanemab slowed decline by 27% over 18 months, this translated to approximately a six-month delay in progression—a clinically meaningful benefit by FDA standards.

Donanemab, a competing monoclonal antibody approved in 2024, showed 35-36% slowing over 18 months. These percentages may sound modest until you remember that we are talking about slowing a disease that currently has no cure; a year of additional independent function matters profoundly to patients and families. The barrier for approval is partly statistical and partly practical. A promising compound must not only show improvement greater than placebo, but the improvement must be large enough and consistent enough across diverse patient subgroups that the FDA can be confident the effect is real. Additionally, all clinical trials in Alzheimer’s have faced historically devastating failure rates. Between 2002 and 2012, the clinical trial failure rate for Alzheimer’s disease was 99.6%—meaning nearly all candidates failed to meet their primary endpoints. Even with modern biomarker-driven patient selection, failure remains common, which is why a therapy that actually succeeds is proven, not merely promising.

Compounds Advancing in Alzheimer’s TrialsPhase 1 Start100%Phase 1 End87%Phase 2 End28%Phase 3 End9%FDA Approved4%Source: NIH/FDA Clinical Trial Data

BIOMARKERS AS THE MODERN DIFFERENTIATOR

Thirty years ago, Alzheimer’s research relied on clinical diagnosis and autopsy confirmation. Today, biomarkers—measurable biological signatures of disease—have become the gatekeeper for both research and therapy. Eighty-four percent of current Alzheimer’s therapeutic trials use biomarkers either as inclusion criteria or as outcome measures, with 91% of Phase 2 trials and 83% of Phase 3 trials incorporating them. This shift reflects a fundamental insight: you cannot develop proven therapy for a disease you cannot reliably identify before advanced symptoms appear. The revolution in biomarker accessibility has accelerated development of promising research into proven therapy. For decades, the only way to measure amyloid and tau in living patients was through expensive, invasive cerebrospinal fluid collection via lumbar puncture, or through specialized PET imaging costing thousands of dollars. In May 2025, the FDA approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test—a blood test that can now identify biomarker positivity with accuracy equivalent to cerebrospinal fluid analysis.

This single development has transformed recruitment for Alzheimer’s trials. The AHEAD 3-45 Study, testing lecanemab in asymptomatic individuals, screened over 20,000 people using the PrecivityAD blood biomarker test to identify amyloid-positive patients before any cognitive symptoms emerged. Without blood biomarkers, such large-scale screening would have been impractical and prohibitively expensive. However, biomarker success creates a hidden danger: the assumption that reversing a biomarker equals reversing disease. A drug can reduce amyloid levels in the brain and still fail to preserve cognition—in fact, this has happened repeatedly in Alzheimer’s drug development. This is why the FDA distinguishes between surrogate endpoints (like amyloid reduction) and clinical endpoints (actual cognitive decline). Promising research often demonstrates surrogate endpoint success; proven therapy must additionally demonstrate clinical endpoint success. The distinction has real consequences: it is why lecanemab required both accelerated approval (based on amyloid reduction) and a postmarketing confirmatory trial (based on cognitive slowing).

BIOMARKERS AS THE MODERN DIFFERENTIATOR

MEASURING MEANINGFUL COGNITIVE DECLINE

One underappreciated requirement that separates promising from proven is the methodology for measuring cognitive change. The ADAS-Cog scale is not arbitrary; it was developed specifically to detect the subtle cognitive changes that occur in early Alzheimer’s disease. Questions test memory, attention, language, and reasoning. Because Alzheimer’s progresses slowly in early stages, detecting real decline requires sensitive instruments and lengthy trials. Most Phase III trials for Alzheimer’s therapies run for 18 months to 2 years—significantly longer than trials for many other diseases—because shorter periods may not capture sufficient cognitive change to demonstrate statistical significance. This long timeline means that disease-modifying therapy development in Alzheimer’s takes approximately 51 months in Phase III trials alone, followed by regulatory review. Compare this to approval timelines for other drugs: a blood pressure medication might be approved after a 12-week trial showing sustained blood pressure reduction. An Alzheimer’s drug must prove it slows a disease that naturally progresses slowly, which requires patience and sustained funding that many smaller companies cannot afford.

The clinical trial infrastructure itself becomes a barrier. Each trial requires specialized cognitive assessment teams, regular patient visits, imaging studies to monitor for safety, and recruitment from populations increasingly aware of and interested in experimental therapies. A final measurement challenge is the heterogeneity of Alzheimer’s disease. Not all patients with cognitive impairment and amyloid positivity progress at the same rate. Some may have additional pathology—tau tangles, Lewy bodies, vascular disease—that affects their cognitive trajectory. An individual patient might show minimal cognitive decline over two years even without treatment, while another might decline rapidly. The FDA requires that trials show benefits across the overall population, with consistent effects across predefined subgroups. This is a high bar that cannot be met by anecdotal reports of individual patients improving on a drug.

Beyond efficacy, the FDA mandates rigorous safety surveillance, which is where many promising therapies have stumbled. Monoclonal antibodies against amyloid can trigger amyloid-related imaging abnormalities (ARIA)—MRI abnormalities that reflect potential inflammation or microhemorrhages in the brain. These appear as ARIA-E (amyloid-related imaging abnormalities-edema), detected as increased fluid in brain tissue, or ARIA-H (microhemorrhages or microinfarcts). In the CLARITY AD trial of lecanemab, 12.6% of treated patients experienced ARIA-E compared to 1.7% in the placebo group. Most were asymptomatic, but some caused cognitive or neurological symptoms including headache, confusion, or vision changes. This safety profile creates a practical barrier between promising and proven therapy: approved drugs must come with prescribing information that clearly delineates which patients can safely receive them. Lecanemab is approved only for mild cognitive impairment or mild dementia due to Alzheimer’s disease—the populations studied in trials.

There is no safety data for moderate or advanced dementia. There is no safety data for patients with severe cerebrovascular disease, a history of stroke, or certain other conditions. A promising drug that appeared to work well in a 1,500-patient trial of carefully selected mild-stage patients cannot simply be prescribed to all Alzheimer’s patients. The FDA approval is population-specific, and prescribing outside that population is prescribing off-label, meaning the treating physician accepts responsibility for safety outcomes not established in trials. The postmarketing requirement that follows FDA approval also reflects this philosophy. Donanemab, approved in July 2024, also came with postmarketing commitments to monitor long-term safety and to assess efficacy in earlier (preclinical) disease stages. Proven therapy is not frozen at the moment of approval; it is a foundation that will be expanded, refined, and monitored across years and decades of real-world use.

SAFETY MONITORING AND AMYLOID-RELATED IMAGING ABNORMALITIES

REAL-WORLD EXAMPLES FROM 2025-2026

The practical developments in 2025 and early 2026 illustrate exactly where promising research transitions to proven therapy. Lecanemab began as a promising candidate: a monoclonal antibody that reduced amyloid in laboratory and animal studies. It graduated to proven therapy only after 18 months of clinical trial evidence. But even approved, lecanemab continues evolving. In January 2026, the FDA approved a new maintenance dosing schedule using intravenous infusion every four weeks instead of bi-weekly, making the therapy more convenient and potentially increasing adherence. In August 2025, the FDA approved subcutaneous weekly injections of lecanemab as maintenance therapy, moving even further toward patient-friendly administration. In May 2026, the FDA set a target action date for at-home weekly subcutaneous starting dose—a development that, if approved, would make Alzheimer’s disease therapy accessible without specialized infusion centers.

Each of these advances started as promising research in formulation development and pharmacokinetics; their approval reflects successful Phase III trials demonstrating safety and efficacy with the new dosing method. Donanemab represents another real-world illustration. As a competing monoclonal antibody, it entered clinical trials after lecanemab had already begun recruitment. The TRONTIER trials, which began enrollment in late 2025, randomized approximately 800 participants each to test donanemab against placebo in tau-driven disease progression—shifting the focus from amyloid-only pathology to tau tangles, the other pathological hallmark of Alzheimer’s. These trials are still ongoing and their results are not yet proven; they remain promising research awaiting evidence. The distinction matters: insurance coverage, FDA approval, and treatment guidelines can only incorporate proven therapies. Physicians cannot confidently recommend TRONTIER trial drugs until data is mature.

THE FUTURE FRONTIER—PREVENTIVE RESEARCH AND ASYMPTOMATIC DISEASE

The frontier separating promising from proven is now shifting from treating symptomatic disease to preventing it. The AHEAD Study, which began enrollment before cognitive symptoms appeared in amyloid-positive individuals, represents this paradigm shift. If asymptomatic amyloid-positive people who receive lecanemab or donanemab show delayed onset of cognitive symptoms compared to placebo, this would prove that disease-modifying therapy works in prevention—a shift with enormous implications for public health. However, this also illustrates the ultimate barrier: proving prevention is even harder than proving treatment.

Prevention trials must be longer, enroll larger numbers, and demonstrate benefit in populations who currently feel well and have no cognitive complaints. PrevenTRON and other planned prevention trials will test tau-targeting agents in asymptomatic disease—using blood biomarkers to identify amyloid- and tau-positive individuals before any brain changes manifest. The regulatory pathway for prevention therapy is still being established; the FDA has not yet approved any drug for asymptomatic Alzheimer’s disease. This is the frontier of promising research, not yet proven therapy, representing both the hope and the uncertainty in modern dementia treatment.

Conclusion

The separation between promising Alzheimer’s research and proven therapy is fundamentally about evidence and risk management. Promising research demonstrates biological effect, shows favorable early signs in laboratory or small human studies, and generates hope. Proven therapy has survived randomized controlled trials involving hundreds or thousands of patients, undergone FDA regulatory review, met statistical standards for clinically meaningful benefit, demonstrated acceptable safety profiles, and achieved approval for specific patient populations. The journey takes years and billions of dollars, with a 99.6% historical failure rate for Alzheimer’s candidates. Lecanemab and donanemab succeeded where nearly all others failed, which is precisely why they represent proven therapy rather than interesting research.

For patients and families currently facing Alzheimer’s disease, understanding this distinction is crucial. Promising research offers hope for future therapy; proven therapy offers real options today, with known risks and established benefits. The pipeline currently contains 138 drugs in 182 clinical trials, with 48 Phase III trials ongoing. Most will fail. Some will succeed and reshape dementia care. The difference will be measured not in press releases or preliminary data, but in rigorous evidence that meets the FDA’s increasingly sophisticated standards for clinical benefit.

You Might Also Like

Browse more: Activities | Alzheimer’s | Aphasia | Blog/News | Books

Related reading

For more on this topic, see National Institute on Aging.

Related Posts